Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: ser), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Serina Therapeutics’ disclosures can feel like navigating polymer chemistry while tracking cash burn. The company’s POZ Platform and multiple neurology trials load its 10-K with dense scientific detail, while 8-Ks can shift outlook overnight as FDA feedback arrives. If you have ever searched hundreds of pages for pipeline timelines or waited anxiously for Form 4 hints of executive confidence, you know the challenge.
Stock Titan solves it. Our AI annotates every document so “Serina Therapeutics annual report 10-K simplified” and “Serina Therapeutics quarterly earnings report 10-Q filing” surface R&D spend, cash runway and upcoming milestones in plain English. Need alerts for “Serina Therapeutics Form 4 insider transactions real-time”? We deliver them alongside contextual trend charts. The platform also labels “Serina Therapeutics 8-K material events explained”, turning raw filings into concise notes within minutes of appearing on EDGAR.
Use these insights to compare trial costs quarter over quarter, review “Serina Therapeutics proxy statement executive compensation”, or dive into “Serina Therapeutics earnings report filing analysis” ahead of capital raises. Whether you’re tracking “Serina Therapeutics insider trading Form 4 transactions”, studying “Serina Therapeutics executive stock transactions Form 4”, or simply “understanding Serina Therapeutics SEC documents with AI”, our real-time feed, AI-powered summaries and expert commentary keep you informed without wading through footnotes.
Randall Moreadith, Chief Scientific Officer of Serina Therapeutics (SER), reported option exercises and immediate sales in August 2025. On 08/18/2025 she exercised 2,227 stock options at a $0.06 strike and sold the resulting shares at $5.25. On 08/20/2025 she exercised 2,077 stock options at $0.06 and sold those shares at $5.10. The filing states the stock options are fully vested. Table entries show derivative holdings after the transactions of 471,263 and 469,186 option-based underlying shares, reported as direct holdings. The reporting person signed the Form 4 on 08/20/2025.
Serina Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025. The current report states the press release is provided as Exhibit 99.1 and that the information is furnished, not filed, meaning it is not automatically incorporated by reference into other SEC filings.
This 8-K does not include the text of the financial results within the report itself; readers must consult Exhibit 99.1 for detailed revenue, expense, profitability or other performance metrics.
Report: Form 4 filed by Moreadith Randall (Chief Scientific Officer) for Serina Therapeutics, Inc. (SER).
Transactions (08/04/2025): The reporting person acquired 5,500 shares of common stock at $0.06 (Table I, Code M) and sold 5,500 shares of common stock at a weighted average price of $5.17 (Table I, Code S); post-transaction common stock beneficially owned: 0. Footnote states sale prices ranged $5.13–$5.35. The reporting person also holds stock options: 5,500 options exercisable through 05/06/2031 and 478,990 derivative securities beneficially owned following the reported transactions (direct). Options are reported as fully vested. Earliest transaction date: 08/04/2025; Form signed 08/05/2025.
Insider transaction summary (SEC Form 4)
On 07/28/2025, Serina Therapeutics (SER) Chief Scientific Officer Dr. Randall Moreadith exercised 6,500 stock options at a strike of $0.06 and immediately sold the resulting shares in the open market. The weighted-average sale price was $5.89 (price range $6.02–$5.60). Net of the option cost, the insider realized roughly $38 k in gross proceeds, while the company received only ~$390 from the option exercise.
After the transactions the officer now holds 0 common shares directly, but still owns 488,686 fully-vested options expiring 05/06/2031. The divestment is immaterial relative to SER’s share count and does not alter overall insider exposure, yet it removes all direct share ownership for this executive.
No other securities, derivatives or accompanying disclosures were reported.
Form 4 snapshot – Serina Therapeutics (SER): On 07/21/2025 Chief Scientific Officer Randall Moreadith exercised 6,500 fully-vested options at an exercise price of $0.06 and immediately sold the same 6,500 common shares in the open market. The weighted-average sale price was $5.34 (range $5.31-$5.40), generating gross proceeds of roughly $34.7 k and eliminating his direct common-stock position, which now stands at 0 shares. He retains 495,186 options after the transaction. The filing reflects a routine option-exercise-and-sell pattern rather than large-scale disposal, but it does reduce immediate share ownership by a named executive.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
